October 17th, 2023 - VANCOUVER, BRITISH COLUMBIAAlbert Labs International Corp. (CSE: ABRT], the "Company" or “Albert Labs”), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet…
September 5th, 2023 - VANCOUVER, BRITISH COLUMBIA Albert Labs International Corp. (Albert Labs (CSE: ABRT) (FSE: VB50), the "Company") announces, effective immediately, that Michael Raymont has resigned from his position…
May 2nd, 2023 - VANCOUVER, BRITISH COLUMBIA Albert Labs International Corp. (CSE: ABRT) (the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet…
Highlights Albert Labs announces expansion of an exciting drug pipeline, broadening the Company’s product portfolio and clinical strategy to additional key jurisdictions and licence indications. This pipeline expansion comes as…
Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange ("CSE") in coordination with its previously announced transaction with ME Resource Corp ("MEC"). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "ABRT" early in the new year.
Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange ("CSE") in coordination with its previously announced transaction with ME Resource Corp ("MEC"). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "ABRT" early in the new year.
Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange ("CSE") in coordination with its previously announced transaction with ME Resource Corp ("MEC"). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "ABRT" early in the new year.
Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange ("CSE") in coordination with its previously announced transaction with ME Resource Corp ("MEC"). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "ABRT" early in the new year.
Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange ("CSE") in coordination with its previously announced transaction with ME Resource Corp ("MEC"). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "ABRT" early in the new year.
Albert Labs, today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange ("CSE") in coordination with its previously announced transaction with ME Resource Corp ("MEC"). Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker "ABRT" early in the new year.
© 2024 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact [email protected]
Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.
